Showing results (31-40 of 34) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
RMD Open|October 18, 2024
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47Josef S Smolen, Jakub Trefler, Artur Racewicz, et al.Arthritis Research & Therapy|February 6, 2021
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized studyJonathan Kay, Janusz Jaworski, Rafal Wojciechowski, et al.Rheumatology (Oxford, England)|June 18, 2021
Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritisDaniel E Furst, Janusz Jaworski, Rafal Wojciechowski, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 22, 2023
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III StudyKim A Papp, Mark G Lebwohl, Diamant Thaçi, et al.Pageof 4